drugset / Trial / NCT04248868

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

NCT04248868

NaSingle-groupOpen-labelTreatment

Summary

To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.

Timeline

Start
2020-06-23
Primary completion
2022-06-22
Completion
2022-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 7 mg Other

Indications